What is Pacific Edge?
Pacific Edge operates at the intersection of biotechnology and clinical oncology, distinguishing itself as a global leader in molecular diagnostic solutions for bladder cancer. The company has developed the Cxbladder suite, a sophisticated, non-invasive diagnostic framework designed to streamline the clinical pathway for patients presenting with haematuria. By providing highly accurate, cost-effective data, Pacific Edge addresses the critical need for precision medicine in both primary investigation and long-term recurrence monitoring. Its market position is defined by a commitment to reducing the burden on public and private healthcare systems while improving patient outcomes through early detection and continuous management.
How much funding has Pacific Edge raised?
Pacific Edge has raised a total of $36.7M across 2 funding rounds:
Stock/Share Issuance
$16M
Other Financing Round
$20.7M
Stock/Share Issuance (2025): $16M, investors not publicly disclosed
Other Financing Round (2025): $20.7M, investors not publicly disclosed
Key Investors in Pacific Edge
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Pacific Edge?
Looking ahead, the strategic deployment of the $20.7M will likely focus on scaling the commercial adoption of Cxbladder across international markets. As the company transitions from a development-heavy phase to a period of rapid commercial expansion, management is expected to prioritize clinical validation studies and the strengthening of distribution partnerships. The focus remains on establishing Cxbladder as the gold standard for urological diagnostics, leveraging the recent capital to enhance infrastructure and support the increasing demand from healthcare providers globally. This growth phase is essential for the company to achieve long-term sustainability and market dominance in the molecular diagnostics space.
See full Pacific Edge company page
